Structure-activity relationships of chromone derivatives toward the mechanism of interaction with and inhibition of breast cancer resistance protein ABCG2

Journal of Medicinal Chemistry

Volumn 56, Issue 24, 2013, Pages 9849-9860

  Winter, Evelyn ^a,b   Lecerf Schmidt, Florine ^c   Gozzi, Gustavo ^a,d   Peres, Basile ^c   Lightbody, Mark ^c   Gauthier, Charlotte ^a   Ozvegy Laczka, Csilla ^e   Szakacs, Gergely ^e   Sarkadi, Balazs ^f   Creczynski Pasa, Taînia B ^b   Boumendjel, Ahcène ^c   Di Pietro, Attilio ^a  

^a UNIVERSITÉ LYON 1   (France)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^c Laboratoire de Pharmacochimie   (France)

^d FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^e INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^f SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,4,6,7,12,12A OCTAHYDRO 6 ISOBUTYL 9 METHOXY 1,4 DIOXOPYRAZINO[1',2':1,6]PYRIDO[3,4 B]INDOLE 3 PROPANOIC ACID TERT BUTYL ESTER; 5 (4 BROMOBENZYLOXY) 2 [2 (5 METHOXYINDOLYL)ETHYL 1 CARBONYL] 4H CHROMEN 4 ONE; 5 (4 BROMOBENZYLOXY) 2 [[[2 (1H INDOL 3 YL)ETHYL]METHYLAMINO]METHYL]CHROMEN 4 ONE; 5 (4 BROMOBENZYLOXY) 2 [[[2 (5 METHOXY 1H INDOL 3 YL)ETHYL]METHYLAMINO]METHYL]CHROMEN 4 ONE; 5 (4 BROMOBENZYLOXY) 4 OXO 4H CHROMENE 2 CARBOXYLIC ACID(1 BENZYL 1H [1,2,3]TRIAZOL 4 YLMETHYL)AMIDE; 5 (4 BROMOBENZYLOXY) 4 OXO 4H CHROMENE 2 CARBOXYLIC ACID[1 (4 BROMOBENZYL) 1H [1,2,3]TRIAZOL 4 YLMETHYL]AMIDE; 5 (4 BROMOBENZYLOXY) 4 OXO 4H CHROMENE 2 CARBOXYLIC ACID[1 [2 (1H INDOL 3 YL)ETHYL] 1H [1,2,3]TRIAZOL 4 YLMETHYL]AMIDE; 5 (4 BROMOBENZYLOXY) 4 OXO 4H CHROMENE 2 CARBOXYLIC ACID[2 (1 METHYL 1H INDOL 3 YL)ETHYL]AMIDE; 5 (4 BROMOBENZYLOXY) 4 OXO 4H CHROMENE 2 CARBOXYLIC ACID[2 (1 METHYL 1H INDOL 3 YL)ETHYL]METHYLAMIDE; 5 (4 BROMOBENZYLOXY) 4 OXO 4H CHROMENE 2 CARBOXYLIC ACID[2 (1H INDOL 3 YL)ETHYL]METHYLAMIDE; 5 (4 BROMOBENZYLOXY) 4 OXO 4H CHROMENE 2 CARBOXYLIC ACID[2 (5 METHOXY 1H INDOL 3 YL)ETHYL]METHYLAMIDE; 5 (4 BROMOBENZYLOXY) 4 OXO 4H CHROMENE 2 CARBOXYLIC ACID[2 (6 METHOXY 1H INDOL 3 YL)ETHYL]AMIDE; 6 (4 BROMOBENZYLOXY) 4 OXO 4H CHROMENE 2 CARBOXYLIC ACID[2 (5 METHOXY 1H INDOL 3 YL)ETHYL]AMIDE; 6 (4 BROMOBENZYLOXY) 4 OXO 4H CHROMENE 2 CARBOXYLIC ACID[2 (5 METHOXY 1H INDOL 3 YL)ETHYL]METHYLAMIDE; 6 (4 BROMOBENZYLOXY) 4 OXO 4H CHROMENE 2 CARBOXYLIC ACID[2 (METHYL 1H INDOL 3 YL)ETHYL]METHYLAMIDE; 7 (4 BROMOBENZYLOXY) 4 OXO 4H CHROMENE 2 CARBOXYLIC ACID[2 (5 METHOXY 1H INDOL 3 YL)ETHYL]AMIDE; ADENOSINE TRIPHOSPHATASE; AMIDE; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CHROMONE DERIVATIVE; INDOLE DERIVATIVE; MITOXANTRONE; NITROGEN; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TRANSPORT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; METHYLATION; STRUCTURE ACTIVITY RELATION;

EID: 84891317018     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401649j     Document Type: Article

References (35)

1. Endicott, J. A.; Ling, V. The biochemistry of P-glycoprotein-mediated multidrug resistance Annu. Rev. Biochem. 1989, 58, 89-101
2. Cole, S. P. C.; Bhardwaj, G.; Gerlach, J. H.; Mackie, J. E.; Grant, C. E.; Almquist, K. C.; Stewart, A. J.; Kurz, E. U.; Duncan, A. M. V.; Deeley, R. G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line Science 1993, 258, 1650-1654
3. Allikmets, R.; Schriml, L. M.; Hutchinson, A.; Romano-Spica, V.; Dean, M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance Cancer Res. 1998, 58, 5337-5339
4. Doyle, L. A.; Yang, W.; Abruzzo, L. V.; Krogmann, T.; Gao, Y.; Rishi, A. K.; Ross, D. D. A multidrug resistance transporter from human MCF-7 breast cancer cells Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 15665-15670
5. Miyake, K.; Mickley, L.; Litman, T.; Zhan, Z.; Robey, R.; Cristensen, B.; Brangi, M.; Greenberger, L.; Dean, M.; Fojo, T.; Bates, S. E. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: Demonstration of homology to ABC transport genes Cancer Res. 1999, 59, 8-13
6. Rabindran, S. K.; He, H.; Singh, M.; Brown, E.; Collins, K. I.; Annable, T.; Greenberger, L. M. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C Cancer Res. 1998, 58, 5850-5858
7. van Loevezijn, A.; Allen, J. D.; Schinkel, A. H.; Koomen, G. J. Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines Bioorg. Med. Chem. Lett. 2001, 11, 29-32
8. Allen, J. D.; van Loevezijn, A.; Lakhai, J. M.; van der Valk, M.; van Tellingen, O.; Reid, G.; Schellens, J. H. M.; Koomen, G. J.; Schinkel, A. H. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C Mol. Cancer Ther. 2002, 1, 417-425
9. Boumendjel, A.; Macalou, S.; Ahmed-Belkacem, A.; Blanc, M.; Di Pietro, A. Acridone derivatives: Design, synthesis, and inhibition of breast cancer resistance protein ABCG2 Bioorg. Med. Chem. 2007, 15, 2892-2897
10. Kühnle, M.; Egger, M.; Muller, C.; Mahringer, A.; Bernhardt, G.; Fricker, G.; Konig, B.; Buschauer, A. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar J. Med. Chem. 2009, 52, 1190-1197
11. Pick, A.; Müller, H.; Wiese, M. Novel lead for potent inhibitors of breast cancer resistance protein (BCRP) Bioorg. Med. Chem. Lett. 2010, 20, 180-183
12. Arnaud, O.; Boumendjel, A.; Gèze, A.; Honorat, M.; Matera, E. L.; Guitton, J.; Stein, W. D.; Bates, S. E.; Falson, P.; Dumontet, C.; Di Pietro, A.; Payen, L. The acridone derivative MBLI-87 sensitizes breast cancer resistance protein-expressing xenografts to irinotecan Eur. J. Cancer 2011, 47, 640-648
13. Valdameri, G.; Genoux-Bastide, E.; Peres, B.; Gauthier, C.; Guitton, J.; Terreux, R.; Winnischofer, S. M.; Rocha, M. E.; Boumendjel, A.; Di Pietro, A. Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein J. Med. Chem. 2012, 55, 966-970
14. Valdameri, G.; Genoux-Bastide, E.; Gauthier, C.; Peres, B.; Terreux, R.; Winnischofer, S. M.; Rocha, M. E.; Di Pietro, A.; Boumendjel, A. 6-Halogenochromones bearing tryptamine: One-step access to potent and highly selective inhibitors of breast cancer resistance protein ChemMedChem. 2012, 7, 1177-1180
15. Hadjeri, M.; Barbier, M.; Ronot, X.; Mariotte, A.-M.; Boumendjel, A.; Boutonnat, J. Modulation of P-glycoprotein-mediated multidrug resistance by flavonoid derivatives and analogues J. Med. Chem. 2003, 46, 2125-2131
16. Lynch, J. K.; Freeman, J. C.; Judd, A. S.; Iyengar, R.; Mulhern, M.; Zhao, G.; Napier, J. J.; Wodka, D.; Brodjian, S.; Dayton, B. D.; Falls, D.; Ogiela, C.; Reilly, R. M.; Campbell, T. J.; Polakowski, J. S.; Hernandez, L.; Marsh, K. C.; Shapiro, R.; Knourek-Segel, V.; Droz, B.; Bush, E.; Brune, M.; Preusser, L. C.; Fryer, R. M.; Reinhart, G. A.; Houseman, K.; Diaz, G.; Mikhail, A.; Limberis, J. T.; Sham, H. L.; Collins, C. A.; Kym, P. R. Optimization of chromone-2-carboxamide melanin concentrating hormone receptor 1 antagonists: Assessment of potency, efficacy, and cardiovascular safety J. Med. Chem. 2006, 49, 6569-6584
17. Somei, M.; Yamada, F.; Kurauchi, T.; Nagahama, Y.; Hasegawa, M.; Yamada, K.; Teranishi, S.; Sato, H.; Kaneko, C. The chemistry of indoles. CIII. Simple syntheses of serotonin, N -methylserotonin, bufotenine, 5-methoxy- N -methyltryptamine, bufobutanoic acid, N -(indol-3-yl)methyl-5-methoxy- N -methyltryptamine, and lespedamine based on 1-hydroxyindole chemistry Chem. Pharm. Bull. 2001, 49, 87-96
18. Pérez, E. G.; Cassels, B. K.; Eibl, C.; Gündisch, D. Synthesis and evaluation of N1-alkylindole-3-ylalkylammonium compounds as nicotinic acetylcholine receptor ligands Bioorg. Med. Chem. 2012, 20, 3719-3727
19. Jenkins, P. R.; Wilson, J.; Emmerson, D.; Garcia, M. D.; Smith, M. R.; Gray, S. J.; Britton, R. G.; Mahale, S.; Chaudhuri, B. Design, synthesis and biological evaluation of new tryptamine and tetrahydro-β-carboline-based selective inhibitors of CDK4 Bioorg. Med. Chem. 2008, 16, 7728-7739
20. Song, H.; Yang, J.; Chen, W.; Qin, Y. Synthesis of chiral 3-substituted hexahydropyrroloindoline via intermolecular cyclopropanation Org. Lett. 2006, 8, 6011-6014
21. Kolb, H. C.; Finn, M. G.; Sharpless, K. B. Click chemistry: Diverse chemical function from a few good reactions Angew. Chem., Int. Ed. 2001, 40, 2004-2021
22. Belei, D.; Dumea, C.; Samson, A.; Farce, A.; Dubois, J.; Biîcu, E.; Ghinet, A. New farnesyltransferase inhibitors in the phenothiazine series Bioorg. Med. Chem. Lett. 2012, 22, 4517-4522
23. Boumendjel, A.; Nicolle, E.; Moraux, T.; Gerby, B.; Blanc, M.; Ronot, X.; Boutonnat, J. Piperazinobenzopyranones and phenalkylaminobenzopyranones: Potent inhibitors ofbreast cancer resistance protein (ABCG2) J. Med. Chem. 2005, 48, 7275-7281
24. Ozvegy-Laczka, C.; Varady, G.; Koblos, G.; Uhelly, O.; Cervenak, J.; Schuetz, J. D.; Sorrentino, B. P.; Koomen, G. J.; Varadi, A.; Nemet, K.; Sarkadi, B. Function-dependent conformational changes of the ABCG2 multidrug transporter modify its interaction with a monoclonal antibody on the cell surface J. Biol. Chem. 2005, 280, 4219-4227
25. Telbisz, A.; Hegedus, C.; Ozvegy-Laczka, C.; Goda, K.; Varady, G.; Takats, Z.; Szabo, E.; Sorrentino, B. P.; Varadi, A.; Sarkadi, B. Antibody binding shift assay for rapid screening of drug interactions with the human ABCG2 multidrug transporter Eur. J. Pharm. Sci. 2012, 45, 101-109
26. Gauthier, C.; Valdameri, G.; Terreux, R.; Kachadourian, R.; Day, B. J.; Winnischofer, S. M.; Rocha, M. E.; Frachet, V.; Ronot, X.; Di Pietro, A.; Boumendjel, A. Investigation of chalcones as selective inhibitors of the breast cancer resistance protein ABCG2: Critical role of methoxy substituents in both inhibition and cytotoxicity J. Med. Chem. 2012, 55, 3193-3200
27. Ozvegy, C.; Litman, T.; Szakacs, G.; Nagy, Z.; Bates, S. E.; Varadi, A.; Sarkadi, B. Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells Biochem. Biophys. Res. Commun. 2001, 285, 111-117
28. Puentes, C. O.; Höcherl, P.; Kühnle, M.; Bauer, S.; Bürger, K.; Bernhardt, G.; Buschauer, A.; König, B. Solid phase synthesis of tariquidar-related modulators of ABC transporters preferring breast cancer resistance protein (ABCG2) Bioorg. Med. Chem. Lett. 2011, 21, 3654-3657
29. Al-Shawi, M. K.; Polar, M. K.; Omote, H.; Figler, R. A. Transition state analysis of the coupling of drug transport to ATP hydrolysis by P-glycoprotein J. Bio. Chem. 2003, 278, 52629-52640
30. Dawson, R. J.; Locher, K. P. Structure of a bacterial multidrug ABC transporter Nature 2006, 443, 180-185
31. Ward, A.; Reyes, C. L.; Yu, J.; Roth, C. B.; Chang, G. Flexibility in the ABC transporter MsbA: Alternating access with a twist Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 19005-19010
32. Aller, S. G.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.; Harrell, P. M.; Trinh, Y. T.; Zhang, Q.; Urbatsch, I. L.; Chang, G. Structure of P-glycoprotein reveals a molecular basis for poly-specificity drug binding Science 2009, 323, 1718-1722
33. Jin, M. S.; Oldham, M. L.; Zhang, Q.; Chen, J. Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans Nature 2012, 490, 566-569
34. Telbisz, A.; Muller, M.; Ozvegy-Laczka, C.; Homolya, L.; Szente, L.; Varadi, A.; Sarkadi, B. Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter Biochim. Biophys. Acta 2007, 1768, 2698-2713
35. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cyto-toxicity assays J. Immunol. Methods 1983, 65, 55-63